The Significance of MicroRNAs in Cancer Development
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Biology".
Deadline for manuscript submissions: 20 September 2024 | Viewed by 51
Special Issue Editor
Interests: miRNA; gene therapy; cancer therapy; gene editing; nanoparticles; PLGA; peptide nucleic acids (PNA); antisense oligonucleotides; tumor targeting; siRNA; RNA therapeutics
Special Issue Information
Dear Colleagues,
MicroRNAs or miRs are small 20–25-non-coding RNAs which regulate the post-transcriptional expression levels of multiple mRNAs. Dysregulation of miRs is well established to contribute in progression, resisting cell death, and metastasis of several human cancers. Both oncomiRs (upregulated) or tumor suppressor (downregulated) miRs contribute in development of cancer. In the last few years, a plethora of studies have reported miRs as hallmarks in all aspects of cancer development. Antisense and miR-mimic strategies focused on correcting miR dysregulation have shown promise not only in pre-clinical studies, but also in cancer patients. Since each miR can alter the expression of multiple mRNAs, including oncogenes or tumor suppressor genes, their role in cancer progression, apoptosis, angiogenesis or resistance is highly intricate. Furthermore, multiple miRs have been reported to be dysregulated in highly aggressive tumors such as glioblastoma or diffuse large B-cell lymphoma. Hence, understanding the mechanisms underlying the role of miRs in cancer development is vital to design effective anti-cancer therapy.
We are sure that this collection will be a useful guide for scientists and clinicians. Data on molecular mechanisms or pathophysiology are essential, and clinical trial/data papers are not acceptable.
Dr. Shipra Malik
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- oncomiRs
- tumor suppressor miRs
- cancer progression
- metastasis
- cancer resistance
- cancer therapy
- biomarkers
- miRNA mimics
- antisense therapy
- gene therapy
